Summanwar, Diana
Ropert, Chelan
Barton, James
Hiday, Rachael
Bishop, Dawn
Boustani, Malaz
Willis, Deanna
Article History
Received: 5 November 2023
Accepted: 27 June 2024
First Online: 11 July 2024
Declarations
:
: Exemption from ethics approval and waiver of informed consent to participate granted: The ethics committee of Kaiser Permanente Washington Human Subjects Review Office waived the need for ethics approval and the need to obtain consent for the collection, analysis and publication of the anonymized data for this non-interventional, quality improvement study. (Application 1477891). This study has been performed in accordance with the Declaration of Helsinki.
: Not applicable.
: Not applicable.
: Dr. Boustani serves as Chief Scientific Officer and co-founder of BlueAgilis; and the Chief Health Officer of DigiCare Realized, Inc. He has equity interests in Blue Agilis, Inc.; DigiCare Realized, Inc.; Preferred Population Health Management LLC; and MyShift, Inc. (previously known as RestUp, LLC). He serves as an advisory board member for Eli Lilly and Co.; Eisai, Inc.; Merck and Co. Inc.; Biogen; and Genentech. These conflicts have been reviewed by Indiana University and have been appropriately managed to maintain objectivity. The remaining authors declare no competing interests.